have been reported to inhibit replication of the human immunodeficiency virus (HIV) both in vitro and in vivo (1:2) . In fact, there are already 11 antiretroviral agents licensed for use in the United States, and many more are currently undergoing preclinical and clinical evaluation. The approved agents include 2',3' dideoxynucleotide analog, reverse transcriptase inhibitors (azidothymidine [AZT] , didanosine, dideoxycytidine, starvudine
[d4T], and lamivudine [3TC]); nonnucleoside reverse transcriptase inhibitors (NNRTIs; Nevirapine, Delavirdine) and protease inhibitors (Saquinavir, Ritonavir, Indinavir, and Nelfinavir) . Multiple clinical trials have demonstrated that treatment with these agents can result in improvement in markers such as CD4 count and viral load (3) (4) (5) . Other studies have suggested that antiretroyiral therapy can improve clinical outcomes such as mortality, occurrence of opportunistic infections, and progression to AIDS (6,7). Combination therapy seems to be superior to monotherapy (8).
Unfortunately, current therapeutic regimens result in suppression but not eradication of HIV. Furthermore, antiretroviral therapy is limited by both drug toxicity and the invariable development of resistance. A variety of studies have demonstrated that resistance is associated with specific mutations in the HIV pol gene (9-12). If it were possible to directly monitor the occurrence of such mutations in the HIV RNA sequence of a given patient, specific alternative therapies might be considered before a surrogate marker (e.g., CD4 count or viral load) could be expected to even reflect a failure of the current regimen. However, detection of drug resistance may only be indicated for those patients with a rise in viral load on therapy based on studies in which continued suppression of HIV RNA was associated with a wild-type genome (7). Furthermore, the clinical application of sequence information in an individual patient may not currently be feasible because of the time and labor required for the sequencing process and subsequent data management.
Fortunately, computer technology can be applied to solve the problem of bulky sequence data management. Rule-based expert systems (13, 14) are computer programs that declaratively represent knowledge of a specialized problem and facts about a specific case? and draw inferences about the case. In the program developed for the current study (Customized Treatment Strategies for HIV [CTSHIV] ), the rules encode information on drug-resistant mutations of HIV and characteristics of current antiviral agents, the facts are the sequences of the HIV genomes obtained from a specific individual, and the inference to be drawn is a set of recommended drug regimens. The knowledge of a specific problem may be represented as a set of weighted if-then rules of the form: IF <antecendent> THEN <consequence>.
For example, one such rule in CTSHIV is: IF Leucine is encoded by codon 4 1 of the RT portion of the pol gene, then do not use AZT (weight = 0.3). The rule is derived from the literature, which reports that a methionine-toleucine mutation at codon 41 confers approximately fourfold resistance to AZT (15). The rules are weighted from 0.1 (low priority) to 1.0 (high priority) based on level of resistance or support in the literature. To draw an inference about a particular conclusion (e.g., which drugs should not be used), the expert system finds rules whose consequence matches that conclusion, and attempts to determine whether the antecedent of the rule is true. If the antecedent can be shown to be true, then the conclusion is asserted to be true. There are two ways in which an antecedent may be true. First, the antecedent may match a fact that is known. For example, in the rule just stated, this would check to see whether there is a leucine encoded by codon 41 of the RT portion of the pol gene. Second, the antecedent may match the consequence of another rule, and the antecedent of that rule can then be shown to be true.
The current study reports a process by which the protease, reverse transcriptase, and integrase segments of the HIV pol gene can be cloned using three primer sets and the sequences downloaded into an expert system that recommends multiple ranked two-, three-, and four-drug regimens based primarily on the occurrence of known mutations coding for specific drug resistance.
METHODS

Cloning and Sequencing
Blood was obtained from 10 HIV-infected individuaIs after informed consent was obtained using a form approved by the Institutional Review Board at UC Irvine, All patients had CD4 counts <500/mm3, two had never received antiretroviral therapy, and the others had received a variety of regimens, Standard reverse transcription-polymerase chain reaction (RT-PCR) was performed using published primer sets for protease (16) and RT (17) and primers developed in our laboratory for integrase downstream 5'.CCTAGCTTTCCCTGAAACATA-CATATGGTG'IT3').
PCR was performed on all 10 patients to demonstrate reproducibility of the primer sets used.
Because cloning and sequencing of PCR products is well standardized, PCR product from only two patients was sequenced. Briefly. a portion of PCR product (calculated to give an approximate vector insert ration of 1: 1) was Iigated into a T/A vector (Invitrogen). Two microliters of the ligation reaction was transferred to a tube containing 50 p,l of competent Eschen'chia coli cells. The bacteria were transformed (18), plated onto Luria-Bertani (LB) agar plates containing 50 pg/ml of kanamycin. and grown at 37°C for 72 h. For each plate, a single white colony was grown overnight in 5 ml of liquid LB broth containing 50 kg/ml of kanamycin. The plasmid DNA was purified and extracted using a Qiagen plasmid preparation kit (Chatsworth, CA). For the two patients, five clones per PCR product were sequenced using a dyetermination process (19) with an automated ABI sequencer. One was asymptomatic and had a CD4 count of 285/mm3 without prior antiretroviral therapy. The other patient had a history of Pneumucvstis carinii pneumonia and mild wasting syndrome, had received multiple antiretroviral regimens, and currently had a CD4 count of 55 cells/mm'.
Development of Rules for the Expert Program
Base substitutions coding for either in vitro and/or resistance to specific drugs (20) (21) (22) (23) (24) were identified in the literature and included as rules for the expert system. The rules were weighted based on the degree of resistance. Additional rules ranked available therapies based on HIV antiviral activity, overlapping toxicities, and mechanisms of action. Currently, there are 48 rules in the program ( Table 1) .
Development of the Expert Program
The CTSHIV system is implemented in first-order computer learning (FOCL-1-2-3) (14), a backward chaining expert system for the Macintosh computer. The facts needed to determine which drugs to exclude are downloaded in CTSHIV. The recommendation process goes through six distinct phases:
1. Exclusion of antiretroviral agents based on sequence information.
The medical literature contains an increasing number of studies on the relationship between mutations and drug resistance. 2. Inclusion of drugs with enhanced antiretroviral activity associated with specific genetic sequences (25) . 3. Exclusion of antiviral combinations with overlapping toxicities, redundant mechanisms of action, or unproven efficacy and/or safety (e.g., NNRTIs used in combination with protease inhibitors). 4. Weighting the aforementioned combinations from 0.1 (low priority) to 1.0 (high priority) based on either: a. level of resistance conferred (phase 1; 2-fold or >lOO-fold resistance were assigned a value of 0.1 or 1.0, respectively; intermediate resistance was assigned a value between 0.1 and 1.0 [22, 23] ), or b. strength of supporting evidence in the literature (phases [2] [3] 125,261). When more than one two, three, or four drug regimens are displayed, rank each regimen by providing a value for each drug within the regimen based on the sum of the weights accumulated from the rules. Rank in descending order the regimens with the lowest total value. In case of equal value: rank in the following order: Indinavir, Ritonavir. Nelfinavir. 3TC, AZT, Delavirdine, Saquinavir, d4T, Nevirapine, ddl. ddC.
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The rules were developed from information in the medical literature and integrated into the FOCL expert system shell. Most of the rules are exclusionary, based on drug-resistant mutations. For example, rule 1 is interpreted as, "Do not use AZT if the nucleotides at codon 41 of the reverse transcriptase portion of the polymerase gene are 'CCT CTC TTA CTA CTG or TTG.' " The parentheses containing the names of drugs or codons represent an "or" between the elements within them. Weights are in brackets, scaled from 0.1 (lowest priority) to 1.0 (highest priority), Exclusionary rules are weighted by the degree of drug resistance conferred. Drug interaction rules are weighted by the severity of overlapping toxicities. Disallowed drug combinations are weighted by the relative lack of supporting evidence in the literature for their use. Each weighted rule is referenced. AZT, azidothymidine: ddl, didanosine; ddC, dideoxycytidine: d4T, starvudine; 3TC, lamivudine.
5. Adjusting the weight of each conclusion by the proportion of clones causing the rule to fire. 6. Identifying and ranking combinations of candidate drugs based on antiviral activity.
RESULTS
Recommended regimens for the study patients: HIV nucleic acid was successfully amplified from all 10 patients using each of the three primer pairs. Complete sequences of five clones from two patients were downloaded into the CTSHIV program and selected regimens choice @a&e 2). Ali five clones frdm patient 1 (CD4 were disulaved in coniunction with exDlanations for their count of 285/mm', no prior antiretrovirals) had identical sequences, including 14 and 6 amino acid substitutions for RT and Pro, respectively, compared with HXB2 (Fig.  1) . None of the changes resulted in the firing of a rule. In contrast, there was great heterogeneity among the five clones from patient 2 (CD4 count of 55/mm3, multiple antiretroviral regimens in the past). There was an average of 47 and 22 amino acid changes for RT and Pro, respectively, firing eight exclusionary rules in the expert program. 
DISCUSSION
Antiretroviral therapy is useful in slowing down the progression of HIV infection. However, all therapeutic regimens studied to date eventually fail, resulting in clinical deterioration of the patient and worsening of surrogate markers such as a rise in CD4 count, an increase in viral load, or both. The current standard of practice indicates a change in therapy when this occurs. However, guidelines as to specific changes in antiretrovirals is lacking, and the possibility of appropriately changing therapy for specific mutants before surrogate marker deterioration is possible. The time to onset of clinically important mutations is highly variable. Cross-resistance occurs between agents in the same class or with similar mechanisms of action (21). Finally, drug-specific resistance mutations also occur in wild-type strains (22). Thus, basing changes in therapy on drug sensitivity would seem to have merit. The results of the current study demonstrate the feasibility of such an approach using an expert program to recommend treatment regimens. The program also encodes information about level of drug resistance, overlapping toxicities, and other factors. Learning algorithms such as FOCL (14) can be applied to the program to modify it based on outcome measures from patients such as CD4 count, viral load, and progression to AIDS. Old rules can be reweighted or eliminated. New rules can be added based on information from the literature or the development of new antiretroviral agents.
The HIV strains in an individual patient are not genomically homogenous. The current system allows detection of a resistant mutation if present in at least one of five clones. If detection of crucial mutations in a patient found less frequently than 20% is later thought to be important, hybridization techniques (27) could be applied to capture those present in as few as 1 of 20 strains.
The CTSHIV system uses primers from conserved regions, yielding detectable PCR products for each of the 10 patients tested. Furthermore, it contains an expert system to effectively manage the sequence data and recommend specific therapeutic regimens based on genetic sequences and information from the medical literature. Nucleotide sequences could be aligned using software programs (28) , reducing the chance of downloading indeterminate foci. However, the current system incorpo- rates sequencing of multiple clones. Although our preliminary studies suggested that such a process both reduces the display of indeterminate residues and enhances the opportunity to identify drug-resistant strains representing a small proportion of the total number of quasispecies in an individual patient compared with sequencing the heterogenous mixture of strains, it also adds significantly to the time and cost. In this pilot study, every effort was made to yield data as cleanly as possible. However, if the system were to be used in the everyday management of patients, sequencing of uncloned, amplified products would be more practical and may yield comparable results. Specialty Laboratories (Santa Monica, CA, U.S.A.) is currently offering genotyping of heterogenous PCR product commercially. Alternatively, rapid sequencing of the polymerase and protease genes in development by Affymetrics (Sunnyvale, CA, U.S.A.) and Applied Biosystems (Foster City, CA, U.S.A.) using fluorescent primer-based cycle sequencing (29) may render the use of the CTSHIV expert system more feasible.
The CTSHIV system is limited by an incomplete understanding of the correlation between genomic mutations conferring drug resistance and clinical and surrogate marker outcomes. Furthermore, the expert program can only incorporate rules from the current literature and recommend licensed drugs. A study to correlate surrogate marker response and clinical outcomes with the use of the program is in progress. In addition, a study by the CPCRA is under way to assess the clinical utility of genotyping (Volberding P, personal communication, February 1997) . Studies with large numbers of patients will ultimately be required to validate the CTSHIV system and determine whether it may assist in the everyday management of HIV-infected individuals and in the design, implementation, and interpretation of outcomes in clinical trials (30) . Currently, however, there is no evidence that the system will perform better than clinical judgment.
